Crossmark

Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin’s lymphoma and primary mediastinal B cell lymphoma

Crossref DOI link: https://doi.org/10.1007/s00277-023-05470-5

Published Online: 2023-09-23

Published Print: 2024-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Panda, Tribikram https://orcid.org/0000-0001-9009-1302
Rainchwar, Sujay https://orcid.org/0000-0003-3040-5968
Halder, Rohan https://orcid.org/0000-0002-3100-558X
Singh, Reema https://orcid.org/0000-0002-4630-0207
Bhurani, Dinesh https://orcid.org/0000-0001-8066-8913
Agrawal, Narendra https://orcid.org/0000-0002-8743-1801
License Information

Text and Data Mining valid from 2023-09-23

Version of Record valid from 2023-09-23
More Information

Article History

Received: 18 August 2023

Accepted: 18 September 2023

First Online: 23 September 2023

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: The authors have no competing interests to declare that are relevant to the content of this article.

Document is current

Any future updates will be listed below